bitopertin Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Bitopertin is a glycine reuptake inhibitor which was under development by Roche as an adjunct to antipsychotics for the treatment of persistent negative symptoms or suboptimally controlled positive symptoms associated with schizophrenia. Research into this indication has been largely halted as a result of disappointing trial results.   Wikipedia

Chemistry

  • SMILES: C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1CCN(c2ncc(C(F)(F)F)cc2F)CC1)C(F)(F)F
  • InChIKey: YUUGYIUSCYNSQR-LBPRGKRZSA-N
  • Mol. Mass: 543.46
  • ALogP: 3.94
  • ChEMBL Molecules:
    bitopertin  
    bitopertin  
More Chemistry

Pharmacology

Alternative names

(4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl)(5-methanesulfonyl-2-(2,2,2-trifluoro-1-methylethoxy)phenyl)methanone | bitopertin | rg1678 | rg 1678 | rg-1678 | ro4917838 | ro-4917838

Organizations (3)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (5)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (5)


 

beta-Thalassemia (Phase 2)

Healthy Volunteers (Phase 1)

Obsessive-Compulsive Disorder (Phase 2)

Protoporphyria, Erythropoietic (Phase 2/Phase 3)

Schizophrenia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 26
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue